Abstract
Lysosomal Storage Diseases (LSDs) comprise a group of over fifty inherited metabolic disorders, with their hallmark feature being deficient catabolism and accumulation (storage) of macromolecules in the lysosomes due to genetic deficiency of specific lysosomal enzymes. The combined incidence of LSDs is estimated to be ∼1 in 7,000 births. LSD symptoms can vary significantly, primarily due to the nature of the gene defect (null or missense mutations) as well as which cells are affected. Cumulatively, LSDs place a significant burden on patients and their families, causing much in the way of morbidity and mortality. Currently, there is no cure for any LSD. This review will describe currently available treatment options for LSD patients, and then focus upon gene therapy prospects for various LSDs. Worldwide, researchers have accumulated significant data in humans affected by LSDs, as well as several small and large animal models. As a result, various viral and non-viral gene transfer platforms have been developed and specifically optimized to treat LSDs. In this review we will describe advances suggesting that the LSDs may be some of the most amenable diseases to treat by gene therapy based approaches. However, to overcome the several remaining limitations encountered by these approaches, a deep understanding of the biology of the LSDs is required, as well as the host innate and adaptive immune responses to the act of gene transfer.
Keywords: Lysosomal storage disease, gene therapy, enzyme replacement therapy, innate immune responses, adaptive immune responses, Golgi apparatus, oncogenesis, glucocerebrosidase, glycogen, nanoparticles
Current Pharmaceutical Design
Title: Gene Therapy for Lysosomal Storage Diseases: Progress, Challenges and Future Prospects
Volume: 17 Issue: 24
Author(s): Sergey S. Seregin and Andrea Amalfitano
Affiliation:
Keywords: Lysosomal storage disease, gene therapy, enzyme replacement therapy, innate immune responses, adaptive immune responses, Golgi apparatus, oncogenesis, glucocerebrosidase, glycogen, nanoparticles
Abstract: Lysosomal Storage Diseases (LSDs) comprise a group of over fifty inherited metabolic disorders, with their hallmark feature being deficient catabolism and accumulation (storage) of macromolecules in the lysosomes due to genetic deficiency of specific lysosomal enzymes. The combined incidence of LSDs is estimated to be ∼1 in 7,000 births. LSD symptoms can vary significantly, primarily due to the nature of the gene defect (null or missense mutations) as well as which cells are affected. Cumulatively, LSDs place a significant burden on patients and their families, causing much in the way of morbidity and mortality. Currently, there is no cure for any LSD. This review will describe currently available treatment options for LSD patients, and then focus upon gene therapy prospects for various LSDs. Worldwide, researchers have accumulated significant data in humans affected by LSDs, as well as several small and large animal models. As a result, various viral and non-viral gene transfer platforms have been developed and specifically optimized to treat LSDs. In this review we will describe advances suggesting that the LSDs may be some of the most amenable diseases to treat by gene therapy based approaches. However, to overcome the several remaining limitations encountered by these approaches, a deep understanding of the biology of the LSDs is required, as well as the host innate and adaptive immune responses to the act of gene transfer.
Export Options
About this article
Cite this article as:
S. Seregin Sergey and Amalfitano Andrea, Gene Therapy for Lysosomal Storage Diseases: Progress, Challenges and Future Prospects, Current Pharmaceutical Design 2011; 17 (24) . https://dx.doi.org/10.2174/138161211797247578
DOI https://dx.doi.org/10.2174/138161211797247578 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adrenomedullin: Roles for Structure and Function in Cardiac or Vascular Tissues
Current Hypertension Reviews Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Hypertension in Type 2 Diabetes Mellitus: Do We Need to Redefine the Role of Sulfonylureas?
Recent Advances in Cardiovascular Drug Discovery (Discontinued) FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research Telomeres, Senescence and Longevity: The Role of Oxidative Stress and Antioxidants
Current Pharmacogenomics Respiratory Syncytial Virus (RSV) Prevention and Treatment: Past, Present, and Future
Cardiovascular & Hematological Agents in Medicinal Chemistry Chest Pain, Panic Disorder and Coronary Artery Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Cardiomyopathy of Pregnancy
Current Women`s Health Reviews AMPK As A Target in Rare Diseases
Current Drug Targets Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Current Medicinal Chemistry Antidotal Effects of Curcumin Against Agents-Induced Cardiovascular Toxicity
Cardiovascular & Hematological Disorders-Drug Targets Role of Oxidative-Nitrosative Stress and Downstream Pathways in Various Forms of Cardiomyopathy and Heart Failure
Current Vascular Pharmacology Oxytocin and Diabetes Mellitus: A Strong Biochemical Relation. Review
Current Diabetes Reviews Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry A Review of Systemic Vasodilators in Low Cardiac Output Syndrome Following Pediatric Cardiac Surgery
Current Vascular Pharmacology Free Fatty Acids: Circulating Contributors of Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Status of Anti-Picornavirus Therapies
Current Pharmaceutical Design 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets